The U.S. market is preparing for a notable rise in Neomycin Sulphate prices in Qx xxxx, as escalating geopolitical and trade conflicts with China and India may jeopardize the pharmaceutical supply chain. As the U.S. contemplates a xxx tariff on pharmaceutical imports from India and has already imposed high duties on comparable products from China, the accessibility of cost-effective active pharmaceutical ingredients (APIs) such as Neomycin Sulphate is experiencing increasing strain.
India, exporting approximately $xx billion in pharmaceuticals to the U.S. each year, possesses the second-largest count of USFDA-approved manufacturing facilities worldwide. It ranks as one of the top five providers of medicines and APIs, such as Neomycin Sulphate, to the U.S., along with Germany, Ireland, Switzerland, and various other European countries. If the suggested tariffs be implemented, Indian exporters might experience significant challenges, while U.S. purchasers could see higher...
